In our study, the zebrafish embryo model of the rhabdoid tumor sample harboring the typical SMARCB1 deletion and a PRKCD (protein kinase C delta) mutation responded best to the EZH2 inhibitor tazemetostat and the multi-kinase inhibitor ponatinib out of 11 tested drug hits. This evidence concerns the gene SMARCB1 and rhabdoid tumor.